4 Healthcare Stock Stories For Monday Afternoon Investment

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Auxilium Pharmaceuticals (NASDAQ:AUXL): Closing price $18.05

On Monday, the specialty biopharmaceutical firm announced positive data for collagenase clostridium histolyticum which is being developed for the potential treatment, upon approval by the FDA, of adult patients suffering from adhesive capsulitis, commonly known as Frozen Shoulder syndrome. FSS is a common, prolonged, painful condition of the shoulder, thought to be caused by increased capsular collagen thickening and subsequent capsular contraction in the shoulder joint, leading to a loss of range of motion in the shoulder. This condition is believed to affect about two to five percent of the general adult population and the full duration of the disease can last from around 1 year to up to 3.5 years.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AUXL

Repros Therapeutics (NASDAQ:RPRX): Closing price $9.59

Repros reports that the American Urological Association  has accepted key data on Androxal for presentation at the annual meeting in San Diego,  May 4-8. The data presented are from a double-blind, placebo and active control evaluation of two doses of Androxal (12.5 and 25mg) with open label on demand Testim gel in 120 patients suffering from secondary hypogonadism over a 3 month period.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

RPRX

Galena Biopharma (NASDAQ:GALE): Closing price $2.08

Share coverage was begun Monday at Needham & Company with a Buy, along with a price target of $3.50. Analyst Chad Messer commented that “Galena is developing NeuVax, a targeted vaccine for breast cancer. NeuVax has already demonstrated increased survival over placebo when given as an adjuvant to standard-of-care. Galena is now enrolling the 700-patient pivotal PRESENT study which will report interim data in fourth quarter 2013 or first quarter 2014. We believe adjuvant vaccine therapy will ultimately become standard of care for many cancer types, and we view NeuVax as one of the leading new product candidates for this revolutionary treatment modality. Galena also recently acquired an approved product for breakthrough cancer pain, giving the company near-term revenue potential and a commercial presence in oncology.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GALE

Vitamin Shoppe (NYSE:VSI): Closing price $49.08

The firm with over 600 retail locations across the United States launches its first internationally-franchised Vitamin Shoppe store in Panama City, Panama. On Monday, March 4 the Vitamin Shoppe opened its doors to customers in Panama City; the franchisee in Panama, Reprico, has been pursuing health and wellness in that country for many years. Director of Retail Stores for Reprico Marta Ferrer said that ”Our grandparents were pioneers in Pharmacy in Panama. We are excited to open a store that can help people feel better and live healthier with the best quality products.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VSI

Don’t Miss: Is Retirement Already Out of Reach for Younger Generations?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business